Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 3Active not recruiting 2Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 11Plasma cell 4Other hematologic neoplasm 3Dermatologic 3Other solid neoplasm 2CNS 2Thoracic 1Sarcoma 1Genitourinary 1Breast 1

Conditions

Solid Tumors 1Immune-related Adverse Events 1

Interventions

pembrolizumab 27Pemetrexed 10Nivolumab 10Cyclophosphamide 10Carboplatin 10atezolizumab 8Specimen Handling 8Cisplatin 8Ipilimumab 6Biopsy 6fludarabine 5Injections 5tislelizumab 4spartalizumab 4Vincristine 4Radiotherapy 4Proton Therapy 4Platinum 4Paclitaxel 4Drug Therapy 4Docetaxel 4Bevacizumab 41,2-diaminocyclohexaneplatinum II citrate 4sintilimab 3durvalumab 3Trastuzumab 3Etoposide 3Cetuximab 3zimberelimab 2trametinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × tocilizumab × Other solid neoplasm × Clear all
NCT03448042 2026-05-28

A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Genentech, Inc.

Phase 1 Active not recruiting
123 enrolled
Other solid neoplasm

Solid Tumors

NCT04375228 2026-02-06

Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)

Columbia University

Phase 2 Active not recruiting
8 enrolled
Other solid neoplasm

Immune-related Adverse Events

Data powered by HemOnc (CC BY 4.0) Colophon âš¡